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Germline mutations within the coding region of CDKN2A have been observed in affected members of melanoma-
prone families. G101W is the most common CDKN2A missense mutation identified to date. It has been reported
in several families from around the world, with a particularly high occurrence in France and Italy. Given the
frequency of this mutation, we were interested in determining whether the mutation resulted from a single origin
or represented a mutational hotspot in the CDKN2A gene. In addition, given the geographical distribution of the
mutation, we examined the date of origination of the mutation and its migratory spread. We examined 10 families
from Italy, 4 families from the United States, and 6 families from France with the G101W mutation. The following
eight markers were employed for the haplotype analysis: IFNA, D9S736, D9S1749, D9S942, D9S1748, D9S1604,
D9S171, and D9S126. Our findings showed no significant evidence for mutational heterogeneity, suggesting that
all studied families derived from a single ancestral haplotype on which the mutation arose. Using maximum-
likelihood methods, we estimated the mutation to have arisen 97 generations ago (1-LOD-unit support interval
70–133 generations) providing some explanation for the wide geographical spread of this common mutation,
particularly in southwestern Europe. The presence of a founder mutation in a defined geographic area can facilitate
carrier detection and genetic counseling and can provide an opportunity to study disease penetrance and the effect
of environmental factors on the background of a common genetic susceptibility.
Introduction
Germline mutations within the coding region of
CDKN2A (MIM 600160) have been observed in af-
fected members of 9p21 linked families with inherited
melanoma (Dracopoli and Fountain 1996; Hayward
1996). The population frequency of CDKN2A muta-
tions, however, remains unknown. Overall, CDKN2A
mutations have been observed in ∼40% of 9p21-linked
families (Hussussian et al. 1994; Soufir et al. 1998) but
the frequency varies considerably across different studies
(Hussussian et al. 1994; Kamb et al. 1994; Goldstein et
al. 1995; Gruis et al. 1995; Holland et al. 1995; Walker
et al. 1995; Borg et al. 1996; Flores et al. 1997; Harland
et al. 1997; Platz et al. 1997; Soufir et al. 1998).
The CDKN2A gene encodes a protein, p16INK4a,
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which binds the cyclin-dependent kinases 4 and 6
(CDK4 and CDK6) inhibiting phosphorylation of the
retinoblastoma protein (pRB). Therefore p16, the first
melanoma-susceptibility gene to have been identified,
negatively regulates progression through G1 into S
phase of the cell cycle (Serrano et al. 1993, 1995). As
such, it is an attractive candidate as a tumor-suppressor
gene.
Many different mutations have been identified in mel-
anoma-prone families from North America, Europe,
and Australasia. Most mutations described to date are
missense mutations scattered throughout the CDKN2A
coding region. Some mutations have been observed only
once (e.g., R58ter, L62P, and L97R), whereas others
have repeatedly been found in different families (e.g.,
G101W, 113insArg, and 225del19). Haplotype analyses
of recurrent mutations (113insArg, 225del19, and G-
34T) in families from the same geographic areas have
shown evidence for common founders (Gruis et al.
1995; Borg et al. 1996; Liu et al. 1999) rather than
mutation hotspots in the CDKN2A gene. In addition,
recent examination of two recurrent mutations from
geographically diverse populations revealed evidence
for a common founder for the M53I mutation and mul-
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Table 1
Ancestry, Mutation, and Genotyping Information on G101W Families
FAMILY LOCATION
ANCESTRY
ORIGIN
NO. OF
REFERENCE
Genotyped
Individuals
G101W
Individuals Affecteds
Genotyped
Affecteds
Typed
Unaffecteds/
Spouses
6101294 Italy (Liguria) Celtic 9 4 3 1 5 Ghiorzo et al. (1999)
6091195 Italy (Liguria) Celtic 1 1 2 1 0 Ghiorzo et al. (1999)
5080994 Italy (Liguria) Celtic 2 1 3 1 1 Ghiorzo et al. (1999)
7070694 Italy (Liguria) Celtic 3 1 2 0 2 Ghiorzo et al. (1999)
6120894 Italy (Liguria) Celtic 1 1 2 1 0 Ghiorzo et al. (1999)
6090595 Italy (Liguria) Celtic 8a 1 4 2a 6 Ghiorzo et al. (1999)
6110894 Italy (Liguria) Celtic 5 3 3 1 2 Ghiorzo et al. (1999)
7091294 Italy (Liguria) Celtic 10 2 4 3b 7 …
FMM 30 Italy (Rome) … 2 2 2 2 0 …
6091098 Italy (Liguria) Celtic 3 3 3 3 0 …
G USA (KS) S. Germany 6 5 5 3 3 Hussussian et al. (1994)
H USA (PA) Germany 4 4 3 3 1 Hussussian et al. (1994)
I USA (PA) S. Germany 5 5 4 2 2 Hussussian et al. (1994)
CC USA (MD) German/Alsatian 3 2 1 1 2 …
1648 France (Alsatian) Celtic 2 4 3 2 0 Soufir et al. (1998)
2548 France (Alsatian) Celtic 2 2 2 1 1 Soufir et al. (1998)
2000 France (SW) Celtic 2 5 3 2 0 Soufir et al. (1998)
1220 France (SW) Celtic 1 3 2 1 0 Soufir et al. (1998)
1379 France (Corsica) Celtic 2 5 6 1 1 Soufir et al. (1998)
1893 Italy (Liguria) Celtic 1 2 ?c 1 0 …
a Includes one inferred genotype.
b One affected individual was typed for 9p markers but was not screened for the G101W mutation.
c Proband, who had multiple primary melanomas, was adopted. Family history is unknown.
tiple origins for the 23ins24 duplication (Pollock et al.
1998).
G101W is the most common CDKN2Amissense mu-
tation identified to date. It has been reported in nu-
merous families from around the world (Hussussian et
al. 1994; Kamb et al. 1994; Goldstein et al. 1995; Whe-
lan et al. 1995; Soufir et al. 1998; Ghiorzo et al. 1999;
Ruiz et al. 1999) with a particularly high occurrence in
France and Italy (Soufir et al. 1998; Ghiorzo et al.
1999). The G101W mutation has been shown to result
in a functionally defective protein yielding an impaired
ability to inhibit the catalytic activity of complexes of
cyclin D1-CDK4 and cyclin D1- CDK6 in vitro (Ranade
et al. 1995), and to inhibit cyclin D1-CDK4 in a re-
constituted pRb kinase assay (Parry and Peters 1996).
Given the frequency of this mutation, we were inter-
ested in determining whether themutation resulted from
a single origin or represented a mutational hotspot in
the CDKN2A gene. In addition, given the geographical
distribution of the mutation, we examined the date of
origination of the mutation and its migratory spread.
In this study, we present 10 families from Italy, 4 fam-
ilies from the United States, and 6 families from France
with the previously reported (Soufir et al. 1998; Ghiorzo
et al. 1999; Goldstein et al. 2000) G101W mutation in
the CDKN2A gene. We have investigated whether the
G101W mutation in families from different countries
represents an independent mutational event or indicates
the presence of a common founder. Analysis of a large
number of genetic markers in the 9p21 region allowed
us to evaluate this possibility in these families. Our find-
ings showed no significant evidence for mutational het-
erogeneity, suggesting that all studied families derived
from a single ancestral haplotype on which themutation
arose. In addition, the mutation was estimated to have
arisen 97 generations ago (1-LOD-unit support interval
70–133 generations) providing some explanation for
the geographical spread of this common mutation. The
presence of a founder effect can facilitate carrier detec-
tion and genetic counseling in southwestern Europe and
can provide an opportunity to study disease penetrance
and the effect of environmental (and modifying genetic)
factors in a more homogeneous setting.
Subjects and Methods
Subjects/Families
Table 1 shows details of the Italian, French, and Amer-
ican families. Written informed consent was obtained
prior to participation, under IRB-approved protocols
from the three study sites (the National Cancer Institute,
the Institut Gustave Roussy, and the University of Gen-
ova). Further information on the geographic location of
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the current and ancestral settlements of the families are
described under Geographic Evidence.
Italian Families
The clinical data for 7 of 10 Italian families (families
6120894, 5080994, 7070694, 6110894, 6090595,
6101294, and 6091195) and isolation of DNA have
been previously described (Ghiorzo et al. 1999). Three
families (7091294, FMM 30, and 6091098) have not
been previously described. Two affected individuals, four
spouses, and three unaffected individuals were genoty-
ped in family 7091294. An additional affected individual
was haplotyped for 9p markers but was not screened
for the G101W mutation. Two affected brothers were
genotyped in family FMM 30. Three melanoma patients
(sister, brother, and his son) were genotyped in family
6091098. In total, 14 patients with cutaneous malignant
melanoma, 20 unaffected relatives, and 9 spouses from
the 10 Italian families with a G101W mutation were
haplotyped. Genotypes of two additional affected mem-
bers were inferred.
French Families
Five French families (1648, 2548, 2000, 1220, and
1379) which harbored the G101W mutation have been
reported elsewhere (Soufir et al. 1998). Three of the fam-
ilies contained at least three patients with melanoma; the
other two families had two melanoma subjects each. The
sixth family (1893) includes a single proband with mul-
tiple primary melanomas. This proband was adopted
and has an unknown family history. Eight melanoma
patients and two unaffected relatives from these six fam-
ilies were haplotyped.
American Families
Four American families from the National Cancer In-
stitute carried the G101W mutation. All diagnoses of
melanoma were confirmed using histologic review of
pathological material or review of pathology reports.
Data for three of the American families (families G, H,
and I) have been previously presented (Hussussian et al.
1994; Goldstein et al. 2000). Briefly, these three families
contained an average of four melanoma patients, with
a median age at diagnosis of 28 years. Eight melanoma
patients, four spouses, and two unaffected family mem-
bers from these three families were haplotyped. The
other family (CC) has not been previously reported. Al-
though this family reported multiple family members
with melanoma, diagnostic confirmation has only been
possible in the proband, who has had multiple mela-
noma tumors. One melanoma patient, one spouse, and
one unaffected mutation carrier were genotyped in this
family.
Genotyping
The following eight markers were employed for the
haplotype analysis: IFNA, D9S736, D9S1749, D9S942,
D9S1748, D9S1604, D9S171, and D9S126. Primer se-
quences were obtained from the Genome Database.
Markers D9S1749 and D9S942 flanked the CDKN2A
gene. D9S1749 is located ∼0.0105 M distal to exon 2
of the CDKN2A gene, the exon containing the G101W
mutation; D9S942 is located ∼0.0015 M proximal to
CDKN2A exon 2.
Genotyping was performed under slightly different
conditions at each of the three study sites. PCR assays
were performed using either 32P-labeled primers and
were electrophoresed through 7 M urea/6%–8% poly-
acrylamide gels and were run alongside a size standard
generated from pBSMB DNA using the forward M13
(lacZ) primer or with fluorescently-labeled primers and
run on ABI 377 or ABI 310 semi-automated sequencers
to determine allele sizes. Marker D9S1749was amplified
using 1.3 M betaine in the PCR reaction. Complete de-
tails of PCR conditions are available on request to the
authors. The molecular results were combined using six
common DNAs typed in each laboratory as allele size
controls for all markers. Allele sizes for all markers ex-
cept D9S736 and D9S126 are comparable with those
from the haplotype study of Pollock et al. (1998).
Control Subjects
A pool of 43 control subjects was used for allele- and
haplotype-frequency estimation. The controls comprised
20 unaffected spouses collected from the Italian families,
2 spouses/unaffected non–mutation carriers from the
French families, and 21 spouses/non–mutation carriers
from the American families. Of the 20 Italian spouses,
9 were from the G101W families and probably come
from the same region (Liguria); the other 11 Italian
spouses belong to p16 wild-type melanoma families and
are from other regions of Italy. Of the American control
subjects, 5 were from the G101W families, and the other
16 were from other American melanoma-prone families.
Dating the Mutation
We used two approaches to calculate when the
G101Wmutation originated. First, we used amaximum-
likelihood (MLE) method developed and kindly pro-
vided by D. Goldgar (Neuhausen et al. 1996, 1998).
Briefly, the joint likelihood of the G101W haplotypes
was written as a function of the recombination fraction
between the disease and each marker, the number of
generations (G) since the mutation arose, and the mu-
tation rate and allele frequencies at each marker locus.
All markers except D9S1749 and D9S942 were assumed
to have a mutation rate of 0.0006. D9S942 was assumed
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Table 2
Haplotype Analysis of G101W Mutation Carriers for 9p Markers
MARKER
HAPLOTYPE FOR FAMILYa
Italian French American
6101294 5080994 7070694 7091294 6090595 6110894 6091098 2000 1648 1379 G H I CC
IFNA 4 3 4 7 3 3 4 3,6 3 2 6 2 6 6
D9S736 3 3 3 3 3 3 3 5 4 4 4 4 4 6
D9S1749 18 20 20 17 19 20 19 21 17 18 18 21 18 15
D9S942 9 9 9 9 9 9 9 11 9 9 9 9 9 9
D9S1748 9 9 9 9 9 10 9 9 9 9 10 9 10 9
D9S1604 2 2 2 2 2 2,1 2,1 2 2 2,1 2 2 2,1 2
D9S171 1 5 5 9 5 5 5 5 1 1 1 1 1 8
D9S126 5 5 7 3 4 3 5,7 4,6 6 6 1 4,6 3,4 6
a Alleles that are part of the common disease-related haplotype are shown in boldface.
to have a mutation rate of 0.002, on the basis of the
large number of alleles ( alleles). D9S1749 wasn = 23
assumed to have a mutation rate of 0.01, on the basis
of both the large number of alleles ( alleles) andn = 32
the observation of mutations within families. Another
parameter, mD, the proportion of families with an inde-
pendent mutation identical to that of the presumed an-
cestral haplotype, was incorporated into the approach
to examine for mutational heterogeneity, in a manner
similar to standard linkage analysis. The MLE method
was used to find the value ofG that best fitted the pattern
of haplotype sharing at the 8 marker loci. When hap-
lotypes could not be determined with certainty, all pos-
sible haplotypes consistent with the observed multilocus
genotypes were considered in the analysis. Approximate
support intervals were calculated by finding the value of
G on either side of the most likely value that had a10-
fold decrease in likelihood. A heterogeneity test of mu-
tation origin was conducted by comparing the likelihood
at the MLE of G and mD with the analogous likelihood,
assuming mD = 0. Each generation was estimated to be
20 years.
Second, we used the approach suggested by Risch et
al. (1995) (designated as “Q method”). Briefly, Q is the
observed frequency of disease chromosomes not carrying
the progenitor marker allele; pN is the frequency of the
progenitor marker allele on normal chromosomes; v is the
recombination fraction between the disease and marker
locus; and G is the number of generations since the ap-
pearance of the mutation. As such, an estimate of the
number of generations since the appearance of the
G101W mutation is G = log[(1 p Q)/(1 p )]/N N
. The two markers flanking the CDKN2A gene,log(1 v)
D9S1749, and D9S942 were used to estimate the age of
the origin of the G101W mutation in the second method.
In a manner similar to the MLE method above, we cal-
culated 90% confidence intervals for G. We used two sets
of data to estimate Q. First, we used the proband from
each family with a known disease chromosome for
D9S1749 or D9S942 ( probands). Second, we usedn = 17
all melanoma cases and mutation carriers, who shared
the same core haplotype ( for D9S1749 andn = 37 n =
for D9S942). This latter approach is likely to be more38
accurate due to inclusion of a larger number of subjects
and the allowance for known recombination events
within the families (Risch et al. 1995).
Geographic Evidence
All Italian families (except family FMM 30; see table
1) come from a very small area (!40 km2) on the eastern
coast of the region of Liguria. The probands from these
families reported that their families have always lived in
this area and that they know of no ancestors who came
from other regions of Italy. All of the American families
had knowledge about their ancestries. Two families (G,
I) migrated from southern Germany in the mid-to-late
1800s. One family (H) migrated from Germany before
the mid-1800s, but their region of origin and date of
migration are unknown. The fourth family (CC) had a
German/Alsatian origin and migrated to America in the
mid-1800s. For the French families, ancestries were ob-
tained by asking for the birthplace of the proband’s
grandparents. Two families were of Alsatian origin; one
family originated in Corsica. Two families came from
the southwest of France (Ardeche, Lozere, and Aveyron,
which are located within close proximity of each other).
The proband of the sixth family was born in Liguria
and was adopted there. No recent migration of the fam-
ilies has occurred.
Results
Haplotype analysis by means of eight polymorphic
markers spanning the CDKN2A locus was performed
on index cases and additional family members (when
available) to determine whether carriers from different
families harbored the same mutation identically by de-
scent. Table 2 shows the disease haplotypes for families
where phase could be determined. Both alleles are in-
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Table 3
Genotype Analysis of 9p Markers Where Phase Is Not Determined
MARKER
GENOTYPE FOR FAMILYa
Italian French
FMM 30 6091195 6120894 1220 1893 2548
IFNA 3,4 3,4 2,3 2,3 4,6 3,3
D9S736 3,2 3,4 3,4 4,5 4,5 4,4
D9S1749 20,23 20,22 19,20 19,21 21,24 18,32
D9S942 9,23 9,9 9,19 9,11 9,4 9,11
D9S1748 9,4 9,4 9,6 9,7 9,7 9,5
D9S1604 2,2 2,1 2,1 2,1 2,1 2,2
D9S171 5,8 5,8 5,2 5,7 5,5 5,9
D9S126 4,6 2,7 3,5 4,6 6,6 4,4
a Alleles consistent with the haplotype from table 2 are shown in
boldface.
dicated for markers for which segregating alleles could
not be unequivocally determined. Table 3 presents gen-
otypes for families that could not be haplotyped. There
were six such families: three Italian (6091195, 6120894,
and FMM 30) and three French (1220, 1893, and 2548).
We determined whether the genotypes for these families
were consistent with the haplotypes of families forwhom
two or three generations were available.
Table 4 shows the ages of origin of the G101W mu-
tation estimated by use of the MLE and Q methods
(Risch et al. 1995; Neuhausen et al. 1996, 1998). In
addition to the families shown in tables 2 and 3, seven
(for the MLE method) and three (for the Q method)
additional French “sporadic” melanoma subjects were
used to estimate the ages of origin of the G101W mu-
tation. These melanoma patients were the only ones in
their families affected by melanoma. In a separate study
testing for CDKN2A and CDK4 mutations in patients
affected by CMM with multiple primary melanoma tu-
mors and no family history of CMM (B. Bressac-de
Paillerets, A. Chompret, and M.-F. Avril, unpublished
data), seven French melanoma patients were shown to
carry the G101W mutation. Genotypes/haplotypes for
these patients were added to the examination of the age
of origin for the G101W mutation. From the MLE
method, the mutation was estimated to have arisen 97
generations ago (1-LOD-unit support interval 70–133
generations) or ∼1940 years ago (1-LOD-unit support
interval 1,400–2,660 years). The results from the Q
method were consistent with that of the MLE method
but with wider confidence intervals in the Q method
because age-of-origin estimates derive from a single
marker. There was no significant evidence for muta-
tional heterogeneity, suggesting that all families studied
represent derivations from a single ancestral haplotype
on which the mutation arose.
The D9S942-D9S1604 haplotype 9-9-2 appears to be
common across all families (table 2), after recombina-
tion over time is allowed for. In addition, the six families
from table 3 all have genotypes consistent with this
disease haplotype. One French family from southwest-
ern France (2000) had the 11 allele at D9S942, rather
than the 9 allele seen in all other families. Similarly,
three haplotyped families carried the 10 allele, rather
than the 9 allele, at D9S1748. We observed a previously
described variation in the allele size of the D9S1749
marker (Pollock et al. 1998), caused by replication slip-
page resulting in the loss or gain of 1 repeat units
during meiosis. This slippage occurred in members of
the same family, as well as across different families.
After allowing for a high mutation rate in D9S1749, a
common allele centering on allele 19 was observed.
Among the haplotyped families, two carried the 17 al-
lele, four carried the 18 allele, two carried the 19 allele,
three carried the 20 allele, and two carried the 21 allele
(table 2). All of the genotyped families carried at least
one of these five alleles (table 3).
A common disease-related haplotype extended fur-
ther in several families and was related to geographic
origin. For example, the two American families from
southern Germany (G and I) carried the same haplotype
from IFNA to D9S171. The Italian families,
who—except for FMM 30—came from a small area on
the eastern coast of Liguria, all carried the sameD9S736
allele (allele 3). In addition, two Italian families
(5080994 and 7070694) also carried identical haplo-
types from IFNA to D9S171. Ignoring 2-bp differences
at D9S1749 increased this number to four haplotyped
Italian families plus two genotyped Italian families con-
sistent with this haplotype. Several French families had
the same haplotype from D9S736 to D9S126, when
replication slippage at marker D9S1749 was allowed
for.
Forty-three controls were typed for the same markers
used in the haplotype analysis for allele- and disease
haplotype–frequency estimation. A core haplotype for
D9S1749-D9S942-D9S1748-D9S1604 could be deter-
mined in 31 of 43 individuals. None of the haplotyped
controls carried the core disease haplotype (0 of 62 hap-
lotypes). In the entire pool (including 12 subjects for
whom phase information was not available), no subjects
carried the disease haplotype. The frequencies of the
G101W-related alleles from the shared core disease hap-
lotype—D9S1749 (alleles 17-21), D9S942, D9S1748,
and D9S1604—were 0.264, 0.088, 0.122, and 0.56,
respectively. Thus, the probability of finding theG101W
haplotype in the general population is very low (i.e.,
1.6 # 103).
Discussion
In this paper, we have analyzed genotypic data from 20
geographically diverse melanoma-prone families from
Italy, France, and the United States with the most fre-
quent CDKN2A mutation so far identified, the G101W
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Table 4
Estimates of the Age of the G101W Mutation
A. MLE Method
Loci Q
Generations (1-LOD
Support Interval)
Years (1-LOD Support
Interval)
IFNA, D9S736, D9S1749, CDKN2A, D9S942,
D9S1748, D9S1604, D9S171, D9S126 … 97 (70–133) 1,940 (1,400–2,660)
B. Q Method
Locus and Group Q Generations (90% CI) Years (90% CI)
D9S1749:
Probands .588 (.392, .784) 115 (60–261) 2,297 (1,200–5,220)
Affecteds and carriers .514 (.379, .649) 90 (57–141) 1,804 (1,140–2,820)
D9S942:
Probands .118 (0.0, .247) 92 (0–210) 1,846 (0–4,200)
Affecteds and carriers .105 (.023, .187) 81 (17–153) 1,630 (340–3,060)
mutation. This mutation has been observed in mela-
noma-prone families fromAustralia, France, Italy, Spain,
and North America; it is the most common CDKN2A
mutation in France and Italy reported to date. Our find-
ings showed no significant evidence for mutational het-
erogeneity, suggesting that all studied families derived
from a single ancestral haplotype on which the mutation
arose. When maximum-likelihood methods were used,
the mutation was estimated to have arisen 97 genera-
tions ago (1-LOD-unit support interval 70–133 gener-
ations). A second method for estimating the origination
of the mutation (Q method) showed results consistent
with the MLE approach.
The age of origin of the G101W mutation depends
on the methods used for estimation purposes (Risch et
al. 1995; Neuhausen et al. 1996, 1998). The MLE
method is particularly sensitive to the marker mutation
rates. Similarly, the estimated distance between the dis-
ease and marker loci, as well as the precise determi-
nation of subjects with the known disease chromosome,
is critical for the Q method. However, both of the meth-
ods, with their different assumptions, produced similar
results, thus permitting an initial examination of the
genetic history of this common mutation. Historical re-
cords suggest a number of hypotheses to explain the
possible geographical spread of the G101W mutation
and its place of origin.
All the Italian families, with the exception of FMM
30, came from a small area on the eastern coast of
Liguria, and no proband ever recalled having ancestors
who came from other regions of Italy. We, therefore,
reviewed the documented Celtic ancestry and genetic
structure of Liguria to try to identify an historical ex-
planation for the geographically dispersed common
founder mutation. Historical evidence supporting the
hypothesis for a remote mutation origin come from ar-
chaeological findings of the late Hallstatt period
(700–500 B.C.) from the Vara Valley, the geographic
center of the area from which the Italian families derive.
The archeological data support the existence of colonies
or outposts of Celts who likely emigrated from the Po
Valley (Hubert 1974), ∼50 miles away.
Archeological evidence from as early as the 16th and
15th centuries B.C. show Celtic peoples in the upper
course of the river Danube and in eastern France. The
Central and Eastern Hallstatt populations (7th–6th cen-
turies B.C.), who spread throughout most of Western
Europe, including the northernmost part of Italy, were
certainly Celtic (Dietler 1995). During the 6th century
B.C., the Celts conquered all of the Rhineland, Belgium,
and north-central France, along with part of the British
Isles and a large portion of the Iberian peninsula. A new
wave of migrations began around 400 B.C. (Kruta
1987; Vitali 1987; Violante 1993), when the Celts took
control of northern Italy and settled the Po valley, as
recorded by Livy(Historiae V). Although Liguria was
inhabited from prehistorical times by the Ligurians,
probably the most ancient Italian population, it appears
that a Celtic tribe moved from the Po Valley, through
the Appennine Mountains, and settled the nearby hills
along the Ligurian coast. This region of Liguria is the
area where the Italian G101W families have been living
for generations.
Further, molecular results confirm the presence of
Celtic populations in a large portion of the Po Valley,
specifically in the provinces of Vercelli, Pavia, and Pia-
cenza. Examination of HLA allele frequencies using
population-based samples from Liguria, Piacenza, Pa-
via, and North Lombardy, revealed the presence of both
ancient Ligurian and Celtic populations (Guglielmino
et al. 1998). Moreover, earlier studies (Piazza et al.
1988) had shown that the genetic structure of present-
day Italy likely reflected ancient patterns dating back to
pre-Roman times. Specifically, the northern regions of
Ciotti et al.: Single Origin for G101W Mutation 317
Italy, under Celtic influence, are well differentiated from
the central-southern regions, and, within the former
group, the western and eastern regions are remarkably
distinct (Pallottino 1984; Rendine et al. 1997).
Alternatively, if the mutation dates to the beginning
of the support interval, 70 generations or 1,400 years
ago (i.e., 600 A.D.), other historical data provide an-
other hypothesis for the spread of the mutation. During
that period, a number of Irish monks began moving
from their homeland towards the continent. In partic-
ular, Saint Columban, an Irish monk born near Leinster
in 540 A.D., began a voyage towards Gaul in 590 A.D.
with a group of companions and established himself in
Burgundy, where he founded three monasteries (An-
negray, Luxeuil, and Fontaine). In 610, for religious
reasons, he was exiled. As an itinerant preacher he trav-
eled through Alsace, the Rhineland, and Switzerland.
He then crossed the Alps and reached Bobbio (Pia-
cenza), in the upper Po Valley, in 612. There he founded
a monastery and died a few years later (Mabillon 1733;
Metlake 1914). Interestingly, Bobbio lies in the tract of
the valley that starts behind the Appenines, 40 miles
from the villages where the Italian families come from.
A recent study has questioned the intergenerational
time intervals frequently used to date origins of muta-
tions (Tremblay and Vezina 2000). Examination of a
large population register from Quebec, Canada sug-
gested that 30 years was a better estimate of intergen-
erational intervals than 20 or 25 years. However, the
study was only able to examine relatively recent times
(e.g., from the 17th century to the present). The appli-
cability of the 30-year intergenerational interval to mu-
tations of remote origin, such as the G101W mutation,
remains unknown. Use of the 30-year generation in-
terval produced a date of origin for the G101W mu-
tation of 2,910 years (1-LOD-unit support interval
2,100–3,990 years), which is still consistent with the
historical evidence for the spread of the mutation in
southwestern Europe.
Haplotype analyses of recurrent mutations (e.g.,
113insArg, 225del19, and G-34T) from geographically
isolated areas have consistently shown evidence for
common founders, rather than mutation hotspots in the
CDKN2A gene (Gruis et al. 1995; Borg et al. 1996; Liu
et al. 1999). However, for few of these mutations have
there been enough families available to estimate the mu-
tation’s age of origination. The results from the present
study are consistent with previous findings that show
common founders for most of the recurrent mutations
in the CDKN2A gene (Gruis et al. 1995; Borg et al.
1996; Pollock et al. 1998; Liu et al. 1999), suggesting
that the CDKN2A gene is relatively stable. The only
recurrent mutation, to date, that does not appear to
derive from a single founder is the 23ins24 mutation
(Pollock et al. 1998). This finding would be expected
on the basis of the inherent instability of the tandem
repeat region that produced the 24-bp insertion.
Whether all founder CDKN2A mutations also have rel-
atively remote origins remains to be tested.
Although it was not possible to unequivocally deter-
mine the precise geographic location where the muta-
tion originated and how it spread around the world, it
is likely that the mutation originated in Southwestern
Europe. In addition, the historical and archeological
records are consistent with the estimated date of the
origin of the mutation, using both theMLE andQmeth-
ods, and the higher frequency of the mutation in South-
western Europe compared to Northern Europe. Addi-
tional families from other geographic areas may help
better discriminate between the various hypotheses for
the origin and spread of this founder mutation.
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